XENE catalyst calendar

Xenon Pharmaceuticals Inc.

Upcoming catalysts
9
Cash runway
31.4 months
Cash & investments
$931M
Phase 3 programs
11

Xenon Pharmaceuticals Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder on October 15, 2026. There are 9 upcoming events on record.

Cash runway is approximately 31.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 14 concluded trials, 86% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Trial Milestone Phase 3
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
January 15, 2027 An Open-Label Study of Azetukalner in Major Depressive Disorder Trial Milestone Phase 3
April 15, 2027 A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures Trial Milestone Phase 3
May 15, 2027 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Trial Milestone Phase 3
January 15, 2028 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Trial Milestone Phase 3
June 15, 2028 A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) Trial Milestone Phase 3
June 15, 2029 An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) Trial Milestone Phase 3
April 15, 2033 An Open-label Study of XEN1101 in Epilepsy Trial Milestone Phase 3

Track XENE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open XENE in the tracker

Recent history

DateEventTypePhase
August 6, 2026 Quarterly results filed (8-K) Earnings —
June 3, 2026 8-K filed: Leadership change Corporate —
May 7, 2026 Quarterly results filed (8-K) Earnings —
April 13, 2026 8-K filed: Leadership change Corporate —
March 13, 2026 8-K filed: Other event Filing —
March 12, 2026 8-K filed: Material agreement, Other event Corporate —
March 9, 2026 8-K filed: Reg FD disclosure Filing —
February 27, 2026 8-K filed: Other event Filing —
February 26, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures Trial Milestone Phase 3
December 1, 2025 8-K filed: Leadership change Corporate —
November 3, 2025 Quarterly results filed (8-K) Earnings —
October 17, 2025 8-K/A filed: Leadership change, Other event Corporate —
October 16, 2025 8-K filed: Leadership change Corporate —
August 11, 2025 Quarterly results filed (8-K) Earnings —
July 3, 2025 8-K filed: Leadership change Corporate —
May 12, 2025 Quarterly results filed (8-K) Earnings —
November 17, 2023 An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE Trial Milestone Phase 3
September 18, 2023 A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder Trial Milestone Phase 2
May 16, 2023 XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy Trial Milestone Phase 3
November 26, 2021 Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101. Trial Milestone Phase 1
October 4, 2021 Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 Trial Milestone Phase 1
September 2, 2021 A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy Trial Milestone Phase 2
December 19, 2018 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 Trial Milestone Phase 1
July 31, 2018 Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 Trial Milestone Phase 1
February 16, 2017 A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.